why choose us

First received: July 06, 2022

Clinical Trial: Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Study Status: Completed

Recruit Status: RECRUITING

Condition: Post-Transplant Lymphoproliferative Disorder

Study Type: INTERVENTIONAL


Official Title: A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies

Brief Summary: This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory).Loncastuximab tesirine is a monoclonal antibody, called loncastuximab, linked to a chemotherapy drug, called tesirine.Loncastuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them.

Read more